Microbot Medical Inc. has announced the receipt of a non-dilutive grant from the Israel Innovation Authority, amounting to NIS 2.15 million (approximately $630,000). This funding will enhance the company's manufacturing capabilities as it prepares for the commercialization of the LIBERTY® Endovascular Robotic System, pending marketing clearance from the U.S. FDA. The grant, awarded solely to Microbot Medical, recognizes the company's recent achievements and the potential market impact of its single-use, disposable robotic system. Currently, the LIBERTY® System is an investigational device awaiting FDA 510(k) clearance and is not yet available for sale in the U.S.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。